LG H&H Sells Avon: The Real Reason Behind the $120M-to-$6M Deal Why LG Household & Health Care Dumped Avon After 7 Years LG H&H Avon Exit Explained

 

💸 Sold for $6M After Buying at $120M? The Real Math Behind LG H&H's Avon Exit

LG Household & Health Care (LG H&H) is finally letting go of Avon, the American cosmetics company it acquired back in 2019 — just over seven years later. The original purchase price was around 145 billion KRW (roughly $120M at the time), while this sale fetched about 8.3 billion KRW (roughly $6M). On paper, the company is reselling at about 6% of what it paid, which looks like a painful deal at first glance. 🔍

But the reason this news is buzzing across the beauty industry isn't just the eye-catching "fire-sale" number. Packed inside this single transaction is the seismic shift the U.S. cosmetics market has undergone over seven years — and the dramatically elevated status of K-beauty. Today, let's dig beneath the surface of the income statement.

📌 What Exactly Happened?

In August 2026, LG H&H filed a disclosure stating it would transfer its 100% stake (60,000,100 shares) in The Avon Company to a firm called Stratford Worldwide. A disclosure is the mandatory process by which a listed company informs shareholders and investors of material business matters — and asset sales like this, which can affect corporate value, must be made public.

The disposal price was $6M, or about 8.35 billion KRW. Notably, the accompanying Canadian entity was handed over for a single dollar — essentially a "we're just grateful you're taking it off our hands" arrangement. The buyer, Stratford Worldwide, is an affiliate of Regent, the global investment firm that already runs Avon International — suggesting the scattered Avon brand is being reconsolidated under one roof. 💰

🧮 The Real Loss Isn't 145 Billion Won

Here's the point most articles quietly skip. The line "bought for 145B, sold for 8.3B" is punchy, but it fails to capture how much LG H&H actually poured into this business.

Follow the money trail: roughly 145 billion KRW for the 2019 acquisition, about 86.1 billion KRW in cash injected via a paid-in capital increase last year, and about 286.3 billion KRW through a debt-to-equity swap right before the sale. Add it all up, and the seven-year total comes to roughly 517 billion KRW.

Two unfamiliar terms appear here. A paid-in capital increase is when a company issues new shares to raise capital — in plain terms, pumping more money into the subsidiary. A debt-to-equity swap converts money previously lent to the subsidiary into shares of equal value instead of collecting it back in cash; no actual money changes hands, but it cleans up the balance sheet by boosting equity. So spending over 500 billion KRW and recovering just 8.4 billion means the real loss is far heavier than the headline number suggests. 🧹

📉 Why Avon Collapsed — A Sales Model Out of Step with the Times

Avon is a company with 130 years of history. Yet its core business model — "social selling" and direct sales — became the seed of its downfall. Direct sales means representatives sell products straight to consumers without a store, while social selling relies on those reps leveraging personal networks. Picture the old door-to-door cosmetics salesperson. Avon once dominated this model, topping global direct-sales revenue (about $11.3B in 2011).

The problem is that how people buy cosmetics has completely changed. Today, shoppers watch reviews on TikTok, compare ingredients on Amazon, and test products at Sephora before buying. Avon's referral-based model rapidly lost steam in this shift toward digital retail. Even LG H&H's R&D muscle couldn't revive a brand whose very sales channel had fallen out of sync with the era. 📱

🔄 The Real Core — From "Buy Someone's Platform to Reach America" to "Win in America with Our Own Brands"

The essence of this deal is a total overhaul of LG H&H's method for cracking the U.S. market. In 2019, the logic was clear: buy Avon's ready-made distribution, logistics, and sales infrastructure across the U.S. and Canada, and ride it to a fast landing in North America. Avon's roughly 700 billion KRW annual revenue made it look like an attractive springboard.

But the 2026 logic is the opposite. Instead of piggybacking on someone else's platform, LG H&H will directly grow its own brands — Dr. Groot, Belif, CNP — across retail and digital channels. Where did this confidence come from? From the fact that K-beauty's status has been completely transformed over seven years. ✨

📈 Confidence Proven by Numbers — Dr. Groot's Turnaround

This strategic pivot isn't just talk — the results back it up. LG H&H's Q1 North American revenue hit 180.8 billion KRW, up 33.9% year-on-year (from 135 billion KRW). More symbolically, that figure surpassed China (180.7 billion KRW) for the first time ever — a signal that LG H&H's overseas structure, once overwhelmingly China-dependent, is being rebuilt from the ground up.

At the center of this rebound is premium scalp-care brand Dr. Groot. It first built recognition on digital channels like Amazon and TikTok, then entered 682 U.S. Costco stores in September 2024, followed by Sephora's online mall in March this year and 400+ Sephora physical stores nationwide. It's a textbook K-beauty success path — an online-validated brand landing in mainstream U.S. retail. The point: the U.S. market LG H&H once tried to enter by buying Avon's distribution is now being opened by the strength of its own brands. So Avon, purchased for infrastructure, naturally lost its reason to exist. 🎯

⚠️ Not a Pure Happy Ending — The Lingering Shadows

The pivot's logic is compelling, but there are shadows worth weighing. First, the recurring-loss pattern. Avon wasn't LG H&H's only North American acquisition — there's also The Crème Shop, in which it took a 68% stake for about 150 billion KRW in 2022, and which has also slumped, with its goodwill plunging. Goodwill is the premium paid above net asset value when acquiring a company, reflecting brand value and future earnings expectations. When the acquired firm underperforms, that goodwill must be written off as a loss (impairment) — no cash leaves, but it eats into book net income. Avon's goodwill was already fully impaired, and Crème Shop is on shaky ground. In other words, the bill from the "buy America through M&A" era isn't fully settled. 🗡️

Second, the risk that comes with the own-brand strategy. Dr. Groot's success is impressive, but it may create a new weakness: over-reliance on a single brand. The U.S. K-beauty market is exploding, but competition is fierce, and the battle for shelf space at Sephora and Amazon will only intensify. Not owning distribution and leaning on others' channels like Sephora or Costco is a double-edged sword — one policy change and things can wobble.

💡 So How Should We Read This Deal?

In sum, this sale wears two faces at once: a failed M&A and a smart strategic correction. Spending 500 billion and recovering 8.4 billion is, coldly, a failure. Yet cutting losses on a company with an outdated sales model and concentrating resources where things are working is textbook "selection and focus." The key insight: seven years ago, the answer to entering America was "buy a local company," but now it's "wield K-beauty as a weapon directly." Avon's sale is less a confirmed loss and more the moment LG H&H swapped an old map for a new one. The things to watch: whether Dr. Groot's formula can be replicated across Belif and CNP, and how the new risk of channel dependence is managed. 🚀

This article is compiled from public disclosures and press reports and is not intended as investment advice. Always base decisions on the latest disclosures and your own judgment. 📎